Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer.
Maria Fernanda Imperio PereiraIsabela Panzeri Carlotti BuzattoHélio Humberto Angotti CarraraFabiana de Oliveira BuonoJurandyr Moreira de AndradeLeonardo Fleury OrlandiniDaniel Guimarães TiezziPublished in: Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia (2024)
Our study failed to demonstrate a survival benefit of extended capecitabine therapy in patients with TNBC with residual disease after NACT. More studies are warranted to better understand the indication of systemic treatment escalation in this scenario.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- phase ii study
- squamous cell carcinoma
- radiation therapy
- sentinel lymph node
- early stage
- metastatic breast cancer
- open label
- phase iii
- electronic health record
- metastatic colorectal cancer
- big data
- stem cells
- randomized controlled trial
- bone marrow
- artificial intelligence
- free survival